🇺🇸 FDA
Patent

US 11230591

CMV neutralizing antigen binding proteins

granted A61PA61P31/22

Quick answer

US patent 11230591 (CMV neutralizing antigen binding proteins) held by The Board of Regents of the University of Texas System expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61P, A61P31/22